Loading
Physical Evaluation / Trabecular Bone Score / Dual-energy X-ray absorptiometry scans · Observational Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned observational study registered at ClinicalTrials.gov (NCT05590949) designed to characterize bone biomarker changes in post-menopausal women with breast cancer after discontinuation of denosumab and aromatase inhibitors. The study is currently recruiting and has not yet posted results; it measures surrogate endpoints (serum CTX and alkaline phosphatase) at 12 months and imaging at multiple timepoints over 24 months. No efficacy, safety, or clinical outcome data are available from this registry record.
Observational. Breast Cancer; Female; age from 18 Years. Intervention: Post- menopausal breast cancer patients. n = 100. 7 sites: United States.
This is a planned observational study registered at ClinicalTrials.gov (NCT05590949) designed to characterize bone biomarker changes in post-menopausal women with breast cancer after discontinuation of denosumab and aromatase inhibitors. The study is currently recruiting and has not yet posted results; it measures surrogate endpoints (serum CTX and alkaline phosphatase) at 12 months and imaging at multiple timepoints over 24 months. No efficacy, safety, or clinical outcome data are available from this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study is not yet informative for clinical decision-making. When results are available, bone biomarker changes after discontinuation of denosumab and aromatase inhibitor therapy may inform risk stratification and monitoring strategies for bone health in this population.
This is an active observational registry study with no results posted; it describes planned enrollment and biomarker endpoints but reports no outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This study is not yet informative for clinical decision-making. When results are available, bone biomarker changes after discontinuation of denosumab and aromatase inhibitor therapy may inform risk stratification and monitoring strategies for bone health in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05590949). This is a study registration, not published results. Lead sponsor: Memorial Sloan Kettering Cancer Center. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 100 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: OTHER: Physical Evaluation; DIAGNOSTIC_TEST: Dual-energy X-ray absorptiometry scans; DIAGNOSTIC_TEST: Trabecular Bone Score. Primary outcome measures: Change in serum carboxy-terminal collagen crosslinks (CTX) , 12 months; Change in bone specific alkaline phosphatase (ALK) , 12 months. Brief summary: The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab. The study team will collect information from 5 standard clinic visits over the course of 24 months. The information will include information about participant health assessments, blood test results, and imaging results. After 24 months, participation in this study will be complete.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.